Intervention

Letrozole

ClinicalTrials.gov intervention label

Clinical trials242
Recruiting36
Common conditions25
Lead sponsors shown15

Clinical trials

60 shown
Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low TrialNCT07391774 · 2026-08-10
RECRUITING
Study of IEV407 as Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast CancerNCT07604571 · 2026-05-28
RECRUITING
BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic DiseaseNCT07492641 · 2026-05-22
RECRUITING
Implementation Study to Describe and Compare Retention Rate and Adherence to Adjuvant Therapy With Ribociclib With and Without Usage of Mobile Application in Patients With HR+ HER2-negative Stage II and III Breast Cancer in Real-world PracticeNCT06905301 · 2026-01-23
RECRUITING
Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid TumorsNCT07288359 · 2025-12-29
RECRUITING
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)NCT07174336 · 2025-12-22
RECRUITING
Non-interventional Study to Assess the Effectiveness and Safety of Ribociclib in the Adjuvant Therapy of Hormone Receptor Positive (HR+) HER2-negative Stage II and III Breast Cancer in Real Clinical Practice in RussiaNCT06930859 · 2025-12-03
RECRUITING
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast CancerNCT07085767 · 2025-11-03
RECRUITING
Dalpiciclib With or Without Entinostat and Letrozole in HR+/HER2- Early Breast CancerNCT07492394 · 2025-09-12
RECRUITING
A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast CancerNCT07054190 · 2025-09-09
RECRUITING
ORION-1: Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid TumorsNCT06998407 · 2025-08-20
RECRUITING
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast CancerNCT06790693 · 2025-04-09
RECRUITING
A Study With NKT5097 for Adults With Advanced/Metastatic Solid TumorsNCT07029399 · 2025-03-25
RECRUITING
Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After SurgeryNCT06348134 · 2025-03-18
RECRUITING
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of RecurrenceNCT06492616 · 2024-09-27
RECRUITING
RADIANT: Pre-op Radiation With Abemaciclib and LetrozoleNCT06139107 · 2024-08-22
RECRUITING
Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast CancerNCT06380751 · 2024-08-01
RECRUITING
Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast CancerNCT06179303 · 2024-07-22
RECRUITING
Phase IIIb Study of Ribociclib + ET in Early Breast CancerNCT05827081 · 2024-02-28
RECRUITING
DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as TreatmentNCT06075953 · 2024-02-17
RECRUITING
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid TumorsNCT06120283 · 2023-12-01
RECRUITING
Trastuzumab Deruxtecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast CancerNCT05900206 · 2023-10-26
RECRUITING
Study of AVZO-021 in Patients With Advanced Solid TumorsNCT05867251 · 2023-08-30
RECRUITING
Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)NCT05891093 · 2023-06-01
RECRUITING
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid TumorsNCT05768139 · 2023-04-17
RECRUITING
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine TherapyNCT05774951 · 2023-03-31
RECRUITING
Pyrotinib Combined With Trastuzumab, Dalpiciclib, Letrozole Versus TCbHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HR +/HER2 + Breast CancerNCT05638594 · 2022-12-20
RECRUITING
Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant TherapyNCT05582499 · 2022-11-01
RECRUITING
Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast CancerNCT05467891 · 2022-09-13
RECRUITING
Letrozole With and Without Simvastatin for the Treatment of Stage I-III Hormone Receptor Positive, HER2 Negative Breast CancerNCT05464810 · 2022-09-02
RECRUITING
A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast CancerNCT04985266 · 2022-03-30
RECRUITING
A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu Positive (HER2+) Breast Cancer (BC)NCT05035836 · 2021-11-16
RECRUITING
Single Cell Immune and Non-immune Correlates of Response to Neoadjuvant AbemaciclibNCT04614194 · 2021-04-15
RECRUITING
Study of PF-07248144 in Advanced or Metastatic Solid TumorsNCT04606446 · 2020-11-16
RECRUITING
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast CancerNCT03424005 · 2018-03-30
RECRUITING
Fertility Preservation Using Tamoxifen and Letrozole in Estrogen Sensitive Tumors TrialNCT03011684 · 2016-07-21
RECRUITING
Roll-Over Study of Alpelisib (BYL719) for Continued Access and Long-Term Safety.NCT07679269 · 2026-12-15
NOT_YET_RECRUITING
Fulvestaciclib Combined With Anti-HER2 and Endocrine Therapy for HR+/HER2+ Advanced Breast CancerNCT07716046 · 2026-10-01
NOT_YET_RECRUITING
Culmerciclib Combined With Letrozole and Dual HER2 Blockade as Neoadjuvant Therapy for HR+/HER2+ Breast CancerNCT07795424 · 2026-09-01
NOT_YET_RECRUITING
Study of ERW316 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid TumorsNCT07570966 · 2026-06-30
WITHDRAWN
Neoadjuvant Letrozole in Postmenopausal Women With Hormone Receptor-Positive, HER2-Negative, Node Positive, Early-Stage Breast Cancer.NCT07394946 · 2026-06-01
NOT_YET_RECRUITING
Clinical Study of SHR-A1811 With or Without Letrozole in Neoadjuvant Therapy for Early-Stage HR-Positive, HER2-Low Breast CancerNCT07305246 · 2025-12-01
NOT_YET_RECRUITING
A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic CancerNCT06630325 · 2025-06-24
TERMINATED
Optimizing Extended Adjuvant Endocrine Therapy in Patients With Breast CancerNCT06223698 · 2025-05-02
NOT_YET_RECRUITING
Multigene Risk Score Combined With Ki-67 Dynamic Assessment in Stratified Neoadjuvant Endocrine Therapy Treatment With or Without CDK4/6 Inhibitors in HR+/HER2- Breast CancerNCT06650748 · 2025-05-01
ENROLLING_BY_INVITATION
Testing Low Dose Tamoxifen for Invasive Breast Cancer, LoTam TrialNCT06671912 · 2025-02-19
SUSPENDED
A Clinical Trial to Compare Efficacy and Tolerability of Atorvastatin in Addition to Endocrine Treatment With Focus on Mechanisms of Resistance to Endocrine Treatment (Fulvestrant/Aromatase Inhibitors) in Patients With Advanced Breast CancerNCT02958852 · 2025-01-02
COMPLETED
Breast Cancer & Antiestrogenic Therapy & BrainNCT06346457 · 2024-04-01
UNKNOWN
BGB-43395 Alone or as Part of Combination Therapies in Chinese Participants With HR+/HER2- Breast Cancer and Other Advanced Solid TumorsNCT06253195 · 2024-04-01
COMPLETED
Sirolimus for Injection (Albumin-bound) in Combination With Endocrine Therapy for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Who Have Failed Standard TherapyNCT06957379 · 2024-02-29
ACTIVE_NOT_RECRUITING
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast CancerNCT06016738 · 2023-11-16
ACTIVE_NOT_RECRUITING
TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast CancerNCT06001762 · 2023-10-05
ACTIVE_NOT_RECRUITING
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)NCT05952557 · 2023-10-05
ACTIVE_NOT_RECRUITING
Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast CancerNCT05909397 · 2023-08-09
ACTIVE_NOT_RECRUITING
SMMART Adaptive Clinical Treatment (ACT) TrialNCT05238831 · 2023-01-30
WITHDRAWN
NeoadjuVAnt muLti-agENT Chemotherapy or Patritumab Deruxtecan With or Without endocrINE Therapy for High-risk HR+/HER2- Breast Cancer - VALENTINE TrialNCT05569811 · 2022-11-25
ACTIVE_NOT_RECRUITING
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast CancerNCT05514054 · 2022-10-04
ACTIVE_NOT_RECRUITING
A Randomized Study Comparing the Immune Modulation Effect of Ribociclib, Palbociclib, and Abemaciclib in ER+/HER2- EBCNCT05766410 · 2022-09-16
UNKNOWN
Roll-over Study to Allow Continued Access to RibociclibNCT05161195 · 2022-07-07
ACTIVE_NOT_RECRUITING
Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) StudiesNCT05226871 · 2022-07-07
ACTIVE_NOT_RECRUITING

Common conditions

Breast Cancer112Metastatic Breast Cancer27Breast Neoplasms20Anatomic Stage III Breast Cancer AJCC v89Anatomic Stage IV Breast Cancer AJCC v89HER2-positive Breast Cancer7Invasive Breast Carcinoma7Advanced Breast Cancer6Estrogen Receptor Positive6HER2-negative Breast Cancer6HER2/Neu Negative6Anatomic Stage II Breast Cancer AJCC v85Postmenopausal5Progesterone Receptor Positive5Prognostic Stage IV Breast Cancer AJCC v85Advanced Solid Tumor4Anatomic Stage I Breast Cancer AJCC v84Anatomic Stage IIIA Breast Cancer AJCC v84Anatomic Stage IIIC Breast Cancer AJCC v84Breast Carcinoma4Early-stage Breast Cancer4HR+/HER2- Breast Cancer4Recurrent Breast Carcinoma4Stage IV Breast Cancer AJCC v6 and v74Advanced Breast Carcinoma3

Trial status mix

COMPLETED104
RECRUITING36
ACTIVE_NOT_RECRUITING30
TERMINATED29
UNKNOWN26
WITHDRAWN8
NOT_YET_RECRUITING6
ENROLLING_BY_INVITATION1
NO_LONGER_AVAILABLE1
SUSPENDED1

Phase mix

PHASE2122
PHASE355
PHASE140
PHASE417
EARLY_PHASE18
NA5

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.